Antiphospholipid syndrome in the year 2009

Česká verzia

Authors: A. Buliková; J. Zavřelová; M. Penka
Authors place of work: Oddělení klinické hematologie Fakultní nemocnice Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc
Published in the journal: Vnitř Lék 2009; 55(3): 253-262
Category: 15th Parizek's Days

Summary

Antiphospholipid syndrome is a prothrombotic disorder characterized by vascular occlusions and/or pregnancy morbidity in the presence of antiphospholipid antibodies. These autoantibodies represent a large and heterogenous family of circulating immunoglobulins usually identified as anticardiolipin antibodies and antibodies directed against β2-glykoprotein I or as lupus anticoagulant. A number of criteria for diagnosis of antiphospholipid syndrome have been proposed. In this review, we focused on long‑term process of diagnostic procedures development and future directions in scientific research in this field.

Key words:
antiphospholipid syndrome – diagnosis

Zdroje

1. Bick RL. Antiphospholidpid thrombosis syndrome. Clin Appl Thrombosis/Hemostasis 2001; 7: 241–258.

2. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983; 287: 1088–1091.

3. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rhematol 1986; 13: 486–489.

4. Alacrón-Segovia D, Delezé M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353–365.

5. Delezé M, Alacrón-Segovia D, Valdéz Macho E et al. Relationship between antiphospholipid antibodies and reccurent fetal loss in systemic lupus erythematosus patients and apparently healthy women. J Rhematol 1989; 16: 768–772.

6. Alacrón-Segovia D, Sánches-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482–489.

7. Asherson RA, Khamashta M, Ordi-Ros J. The “primary” antiphospholipid syndrome. Major clinical and serological features. Medicine 1989; 68: 366–375.

8. Alacrón-Segovia D, Pérez-Vézquez ME, Villa AR et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Sem Arthr Rheumat 1992; 21: 275–285.

9. Piette JCh, Wechsler B, Frances C et al. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1802–1804.

10. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheumat 1999; 42: 1309–1311.

11. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

12. Dunn AS, Kaboli P, Halfdanarson T et al. Do patients followed in anticoagulation clinics for antiphospholipid syndrome meet criteria for the disorder? Throm Haemost 2005; 94: 548–554.

13. Harris EN, Gharavi AE, Boey ML et al. Anticardiolipin antibosides detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 55: 1211–1214.

14. Green D, Hougie C, Kazmier FJ et al. Report of the working party on acquired inhibitors of coagulation: Studies of the “Lupus anticoagulant”. Thromb Haemost 1983; 49: 144–146.

15. Harris EN, Gharavi AE, Petel SP et al. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215–222.

16. Harris EN. The second international anti‑cardiolipin standardization workshop/the Kingston antiphospholipid study (KAPS) Group. Am J Clin Patphol 1990; 94: 476–484.

17. Barna LK, Triplett DA. A report of the first international workshop for lupus anticoagulant identification. Clin Exp Rheumatol 1991; 9: 557–567.

18. Exner T, Triplett DA, Taberner D et al. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of lupus anticoagulants. Thromb Haemost 1991; 65: 320–322.

19. Swadzba J, Iwaniec T, Szczeklik A et al. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune disease. J Thromb Haemost 2007; 5: 1883–1889.

20. Ruffatti A, Olivieri S, Tonello M et al. Influence of different IgG anticardiolipin antibody cut‑off values on antiphospholipid syndrome classification. J Thromb Haemtos 2008; 6: 1693–1696.

21. Galli M, Reber G, de Moerloose P et al. Invitation to a debate on the serological criteria that define the antiphopsholipid syndrome. J Thromb Haemost 2008; 6: 399–401.

22. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048–1049.

23. Swadzba J, Musial J. Letters to the Editor. More on: The debate on antiphospholipid syndrome classification criteria. J Thromb Haemost, accepted for publication on 19 December 2008.

24. Ruffatti A, Pengo V. Antipospholipid syndrome classification criteria: comments to the Letter of Jakub Swadzba and Jacek Musial. J Thromb Haemost, accepted for publication on 19 December 2008.

25. Pengo V, Biasiolo A, Bison E et al. Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti‑beta2-Glycoprotein I activity. Thromb Res 2007; 120: 127–133.

26. Tincani A, Allegri F, Balestrieri G et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553–558.

27. de Laat B, Derksen RHWM, Urbanus RT et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 2009; 105: 1540–1545.

28. Brandt JT, Triplett DA, Alving B et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–1190.

29. Greaves M, Cohen H, Machin SJ et al in behalf of the Haemostasis and Thrombosis Task Force of British Committee for Standards in Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. B J Haematol 2000; 109: 704–715.

30. Pengo V, Biasiolo A, Gresele P et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5: 925–930.

31. Tripodi A, Biasiolo A, Chantarangkul Vet al. Lupus anticoagulant (LA) testing. Performance of clinical laboratories assessed by a national survey employing lyophylized affinity-purified immunoglobulin with LA activity. Clin Chem 2003; 49: 1608–1614.

32. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048–1049.

33. Tripodi A. More on: criteria to define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1049–1050.

34. Triplett DA, Stocker KF, Unger GA et al. The textarin/ecarin ratio: confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925–93.

35. Zavřelová J, Matýšková M, Buliková A. Textarinový čas v diagnostice lupus antikoagulans. Sborník přednášek – Pracovní dny laboratorní hematologie. Hradec Králové 1998: 61.

36. Tripodi A, Chantarangkul V, Clerici M et al. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russel viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002; 88: 583–586.

37. Wenzel C, Stoiser B, Locker GJ et al. Frequent development of lupus anticoagutants in critically ill patients treated intensive care conditions. Crit Care Med 2002; 30: 763–770.

38. Pengo V. Lupus anticoagulat/phospholipid-dependent antibodies. SSC ISTH Vienna, Austria 3 July 2008; on line publication in ISTH SSC web pages.

39. Favaloro EJ. Preanalytical variables in coagulation testing. Blood Coagul Fibrinolysis 2007; 18: 86–86.

40. Moffat KA, Ledford-Kraemer ME, Plumhoff EA et al. Are laboratories following published recommendations for lupus anticoagulant testing? Thromb Haemost 2009; 101: 178–184.

41. Chang S. More on: normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. J Thromb Haemost 2004; 2: 1480–1481.

42. Tripodi A. Laboratory testing for Lupus anticoagulants: A review of issues affecting results. Clin Chemistry 2007; 53: 1629–1635.

43. Buliková A, Penka M. Antifosfolipidový syndrom – diagnotika a léčba. Vnitř Lék 2005; 51: 809–817.

44. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242–248.

45. Giannakopoulos B, Passam F, Ioannou Y et al. How we diagnose the antiphospholipid syndrome. Blood 2009; 113: 985–994.

46. Ames PRJ, Ciampa A, Margaglione M et al. Bleeding and re‑thrombosis in primary antiphospholipid syndrome on oral anticoagulation. Thromb Haemost 2005; 93: 694–699.

47. Wittkowsky AK, Downing J, Blackburn Jet al. Warfarin‑related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137–141.

48. Kearon C, Julian JA, Kovacs MJ et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112: 4432–4436.

49. Tebo AE, Jaskowski TD, Phansalkar AR et al. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol 2008; 129: 870–875.

50. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644.

51. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody‑induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222–1226.

52. Rotar Z, Rozman B, deGroot PG et al. Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? Lupus 2009; 18: 53–60.

53. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthrit Rheumat 2007; 56: 2382–2391.

54. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577–583.

55. Rand JH, Wu X-X, Quinn AS at al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687–1695.

56. Neville C, Rauch J, Kassis J et al. Antiphospholipid antibodies predict imminent vascular events independly from other risk factors in a prospective cohort. Thromb Haemost 2009; 101: 100–107.

57. Atsumi T. New therapeutic targets for antiphospholipide syndrome. Blood 2007; 110: 4141.